PubMed Health⌕ Search

PubMed · 8718332

Experimental designs.

Abstract

This article discusses randomized clinical trials, double blind designs and factorial designs and describes and explains their main requirements. It is shown that the randomized clinical trial is not a different experimental design, but is one that reflects the purpose for and the scale on which the post-test only or pre-test/post-test designs are often used. A common method for the prevention of experimenter bias in clinical trials is the double blind trial. Factorial designs make the simultaneous manipulation of two or more independent variables possible, thus producing data about their effect on the development variable.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Behi, M Nolan. Experimental designs.. https://doi.org/10.12968/bjon.1996.5.12.754. https://pubmed.health/record/pubmed%3A8718332/experimental-designs

Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.

KEEP EXPLORING

Related citations

Redefining response in overactive bladder syndrome.

OBJECTIVE: To evaluate three potential definitions of treatment response in overactive bladder (OAB) syndrome, based on the International Continence Society (ICS) definition of OAB, using pooled data from two large clinical trials of the antimuscarinic agent solifenacin succinate. PATIENTS AND METHODS: As the ICS definition of OAB does not rely on urodynamic observations for a diagnosis, the use of composite endpoints, such as in the definitions examined here, might provide a more relevant measure of patient benefits. Each definition was tested to assess the impact of pharmacotherapy, comparing treatment response rates based on composite endpoints. Responder definitions were validated based on the impact on quality of life (QoL). Pooled data from two 12-week multinational, multicentre, double-blind randomized studies of solifenacin, a once-daily oral antimuscarinic for treating OAB symptoms, were used for this analysis. Based on the symptom data from these studies (episodes of urgency, incontinence, nocturia and voiding frequency per 24 h), response was defined as being: (i) a reduction by half or more in all baseline symptoms; (ii) a reduction by half or more in urgency and at least one other symptom; or (iii) resolution of urgency episodes and at least one other symptom. Health-related QoL changes were recorded using the King's Health Questionnaire (KHQ). RESULTS: Solifenacin at 5 mg or 10 mg once daily resulted in significantly higher response rates than with placebo, irrespective of the definition of a responder (P < or = 0.001). When assessing the most challenging definition of response (resolution of urgency and at least one other symptom), solifenacin at 5 mg and 10 mg resulted in 20% and 25% of patients, respectively, meeting the response criteria, vs 12% of placebo-treated patients (P < or = 0.001 for both solifenacin doses). For all three definitions of response, responders showed greater improvements in all KHQ domains than did nonresponders, and the differences were statistically significant. CONCLUSIONS: The two strictest definitions of response (halving or more in all baseline symptoms or resolution of urgency and more than one other symptom) appeared to capture QoL changes most effectively. Establishing the most appropriate definition to assess treatment-related changes in OAB will require further investigation, but it is clear from this analysis that composite clinical endpoints, based on the ICS definition of OAB, are a valid approach for assessing the effect of treatments for OAB.

Double-Blind Method↗